| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
5 companies
Norwalk Leslie V serves as a Director at ARVN and has filed Form 4s across 5 companies. Across recent SEC filings that breaks down to 0 buys and 11 sells. Those positions are worth an estimated $2.2M at current prices.
Historically, Norwalk Leslie V's trades have earned a middling insider score of 64/100 across 8 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +2.4%.
The biggest single holding is GMED (~$1.1M) as Director. The recent filings there lean toward selling, a net 17,590 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | NBIX Neurocrine Biosciences, Inc. | Director | Sale+OE10b5-1 | 1,250 | $182.01 | $227,507.50 | -44.0% | -21.9% | - | |
| Jun 4, 2026 | NBIX Neurocrine Biosciences, Inc. | Director | Sell10b5-1 | 1,250 | $168.06 | $210,071.63 | -30.6% | -5.7% | - | |
| May 12, 2026 | NBIX Neurocrine Biosciences, Inc. | Director | Sell10b5-1 | 3,810 | $155.01 | $590,601.05 | -61.1% | +5.9% | - | |
| Jan 8, 2026 | Director | Sell10b5-1 | 2,000 | $101.10 | $202,200.00 | -16.1% | -2.8% | - | ||
| Dec 16, 2025 | NBIX Neurocrine Biosciences Inc | Director | Sale+OE10b5-1 | 6,190 | $152.78 | $945,701.91 | -49.8% | -12.7% | - | |
| Dec 12, 2025 | Director | Sell10b5-1 | 4,000 | $88.85 | $355,400.00 | -24.4% | -2.5% | - | ||
| Jul 11, 2024 | Director | Sell10b5-1 | 1,000 | $70.00 | $70,000.00 | -5.7% | -0.4% | -19.3% | ||
| May 17, 2024 | NBIX Neurocrine Biosciences Inc | Director | Sale+OE10b5-1 | 1,106 | $141.82 | $156,849.93 | -52.7% | +3.9% | -14.9% | |
| Mar 15, 2024 | Director | Sell10b5-1 | 10,590 | $51.99 | $550,574.10 | -37.8% | +28.2% | +38.2% | ||
| Feb 27, 2024 | NBIX Neurocrine Biosciences Inc | Director | Sale+OE10b5-1 | 8,000 | $135.67 | $1,085,388.00 | - | +3.3% | -13.6% |